Source: Network
Near the New Year, the listed company Shunyi Co., Ltd. succeeded in attracting market attention with a "toxic" announcement. With the 7-sheet transaction record, the listed company's "Breaking Bad" was staged in the A-share market.
On January 25, the shares of Shunyu shares closed up 10.04%, setting a historical record of the company's daily limit of 7 consecutive trading days. The company's share price increased from 4.16 per share on January 16 to 8.11 per share, an increase of 94.95%. Almost doubled.
The driving force of the skyrocketing is that the company has obtained the legal “poison†power. On the evening of January 16, Shunyi announced that the company's wholly-owned subsidiary Yunnan Green New Biopharmaceutical Co., Ltd. (Yunnan Green New) has obtained the “Yunnan Industrial Cannabis Planting Permit†and has increased its business scope: Scientific research, planting, processing and sales of industrial cannabis (production and operation within the scope of the license).
In fact, industrial cannabis is not very relevant to drugs. It refers to cannabis varieties with toxicity and THC (tetrahydrocannabinol) content of less than 0.3%. It does not have the value of drug use, and is mainly used in medicine, food, textile, construction, etc. field. Industrial cannabis has high economic value, and the CBD (cannabisphenol) contained in cannabis is a non-addictive ingredient with a variety of medical uses and other uses.
China's current cannabis cultivation is only one type of industrial cannabis, and planting and processing needs to be approved by the local public security bureau. At present, only Yunnan (starting from 2010), Heilongjiang (since 2017), and Jilin (since 2018) are approved to allow legal research and development, planting, processing and sales of industrial cannabis. Yunnan is an important source of cannabis in the world. one.
According to Brightfield Group, the global CBD (industrial cannabis extract) industry value will reach 5.7 billion in 2019, and will reach 18.1 billion in 2021, and is still in the early stages of development. At present, the gross profit rate of processing industrial cannabis is 20-30%, and the production of medical cannabis has a higher added value, and the average gross profit margin is about 60%.
Shanghai Shunyu New Material Technology Co., Ltd. (established on December 21, 2004 as a wholly-owned manufacturing enterprise of Hong Kong businessmen) is a high-tech enterprise and a foreign-invested advanced technology enterprise integrating R&D, manufacturing and sales of environmentally-friendly packaging materials. . The company was listed on the Shenzhen Stock Exchange on March 18, 2011.
The company's main business is engaged in vacuum aluminum-plated paper, laminated paper, optical security film, white cardboard and other environmentally friendly packaging materials, printed matter, three-dimensional free-form environmentally friendly packaging materials, micro-structured optical packaging materials, electronic cigarettes, organic fertilizer research and development , production, processing and sales, and soil remediation and management.
Editor in charge: Ge Hongyan
This article is posted on this website for the purpose of transmitting more information and does not imply endorsement of its views or confirmation of its description.
Article source address: http://
Injectable Dermal Fillers provide a minimally invasive approach to reducing facial lines and wrinkles and restore volume to the face. Due to their popularity and benefits, plastic surgeons are finding ways to maximize the benefits. A recent study suggests that dermal fillers provide varying degrees of lifting and volumizing effects for each patient.
Scans were taken of the cadavers after dermal fillers were injected and showed significant increases in local soft tissue volume in central areas of the face. By targeting these areas, the facial injections provided local lifting effects, however, the benefits were extremely localized with no accompanying regional effects. But, when dermal fillers were injected in lateral areas such as the temple, mid-face, and jawline, the fillers not only created localized lifting but also regional lifting in neighboring areas of the face.
With these findings, plastic surgeons are seeing the importance of combined injection techniques to provide larger benefits for their patients. For example, if a plastic surgeon added a deep filler injection and a temple injection, the technique provided an additional 17.5 percent increase in lifting the temple, plus a 100 percent increase in lifting the jawline.
Face Dermal Filler Injection,Hyaluronic Acid Fillers,Dermal Filler Injection,Fillers For Smile Lines
Rimless Industry Co.,Ltd. , https://www.rimlessmedbeauty.com